Last reviewed 2026-04-20 · How we verify

Inomax (NITRIC OXIDE)

Inomax (nitric oxide) is a vasodilator medication originally developed by INO and currently owned by Vero Biotech Inc. It targets soluble guanylate cyclase to treat persistent pulmonary hypertension of the newborn and pulmonary hypertension. Inomax is a small molecule modality that was FDA-approved in 1999. The commercial status of Inomax is not fully disclosed, but it is available from generic manufacturers. Key safety considerations include the potential for oxygen toxicity and the need for careful monitoring.

At a glance

Approved indications

• Persistent pulmonary hypertension of the newborn
• Pulmonary hypertension

Common side effects

• Hypotension
• Chest discomfort
• Dizziness
• Dry throat
• Dyspnea
• Headache

Serious adverse events

• Hypoxemia
• Worsening Heart Failure
• Intracranial hemorrhage
• Grade IV hemorrhage
• Periventricular leukomalacia
• Cerebral infarction
• Seizures
• Pulmonary hemorrhage
• Gastrointestinal hemorrhage

Key clinical trials

• Role of Genetic Factors in the Development of Lung Disease
• PMPR and Chlorhexidine on Periodontal Disease and Vascular Function (NA)
• Natural History of Sickle Cell Disease
• Use of fenoTRACK Device for Monitoring Changes of Fractional Exhaled Nitric Oxide (FeNO) in Uncontrolled Asthma Subjects and Controlled Asthma Subjects
• Impact of E-cigarette Use on the Body
• Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 (PHASE2)
• NO Prevention of COVID-19 for Healthcare Providers (PHASE2)
• Nitric Oxide (NO) and Endothelial Dysfunction in Women With PTSD (NA)

Patents

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.